Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aran Research & Development (1982) (XTAE:ARAN) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Aran Research & Development (1982) Net Margin % Related Terms
Aran Research & Development (1982) Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aran Research & Development (1982) Net Margin % Chart
For the Conglomerates subindustry, Aran Research & Development (1982)'s Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aran Research & Development (1982) Net Margin % vs Conglomerates Industry
For the Conglomerates industry and Industrials sector, Aran Research & Development (1982)'s Net Margin % distribution charts can be found below:
* The bar in red indicates where Aran Research & Development (1982)'s Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aran Research & Development (1982) (XTAE:ARAN) has a Net Margin % of 9.78% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Aran Research & Development (1982) and its competitors. This is 98% above median its historical median of 4.95. Over the past decade, Aran Research & Development (1982)'s Net Margin % has ranged from 2.04 to 13.60. According to the industry distribution chart, Aran Research & Development (1982) ranks #202 out of 543 companies in the Conglomerates industry, placing it in the top 37.2%.
Is Aran Research & Development (1982)'s Net Margin % too high?
Aran Research & Development (1982)'s current Net Margin % of 9.78% is 98% above median its 10-year median of 4.95. Over the past 10 years, this metric has ranged from a low of 2.04 to a high of 13.60. The Conglomerates industry median Net Margin % is 4.34. Aran Research & Development (1982)'s value of 9.78% is 125.3% above this industry median. Based on the distribution chart, Aran Research & Development (1982) ranks #202 out of 543 companies in the Conglomerates industry, which is above the industry midpoint. Overall, Aran Research & Development (1982) has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Aran Research & Development (1982)'s Net Margin % compare to MMM and HON?
According to the Conglomerates industry distribution chart, Aran Research & Development (1982) ranks #202 out of 543 companies for Net Margin %. This puts Aran Research & Development (1982) in the upper half of its industry. The industry median Net Margin % is 4.34. Aran Research & Development (1982)'s value of 9.78% is 125.3% above this benchmark. Historically, Aran Research & Development (1982)'s own Net Margin % has ranged from 2.04 to 13.60 over the past decade. While the company's 10-year median is 4.95 vs. the industry median of 4.34, Aran Research & Development (1982) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Conglomerates company?
The median Net Margin % among Conglomerates companies is 4.34, based on 543 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aran Research & Development (1982)'s current Net Margin % of 9.78% is 125.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Aran Research & Development (1982) and its competitors. For the Conglomerates industry, the median Net Margin % is 4.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aran Research & Development (1982)'s current Net Margin % is 9.78%, which is 98% above median its own 10-year median of 4.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aran Research & Development (1982) stock overvalued right now?
Based on GuruFocus' analysis, Aran Research & Development (1982) (XTAE:ARAN) is currently considered Fairly Valued. The stock's GF Value™ is ₪37.11, compared to a current price of ₪39.78 — trading 7.2% above its estimated fair value. The current Net Margin % is 9.78%, which is 98% above median its 10-year median of 4.95 and 125.3% above the Conglomerates industry median of 4.34. Aran Research & Development (1982)'s overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Aran Research & Development (1982) (XTAE:ARAN), the current Net Margin % is 9.78% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aran Research & Development (1982) (XTAE:ARAN) Overvalued in 2026?
Based on GuruFocus' analysis, Aran Research & Development (1982) stock appears to be overvalued.
The current stock price of ₪39.78 is trading 7.2% above its estimated GF Value™ of ₪37.11.
GuruFocus considers Aran Research & Development (1982) to be Fairly Valued.
Key valuation signals for XTAE:ARAN:
Net Margin %: 9.78% (98% above median its 10-year median of 4.95)
GF Value™: ₪37.11 vs. price of ₪39.78 (7.2% above fair value)
Industry Position: 125.3% above the Conglomerates median (#202 of 543)
No single metric tells the full story. See the XTAE:ARAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aran Research & Development (1982) Ltd is a product design and development company. It also manufactures equipment for the plastics industry. It develops & supplies products including medical devices, water, defense & HLS, consumer & industrial and injection molds. It also has medical startups which focuses on Cardiovascular, Laparoscopy and Gastrointestinal endoscopy.
78GF Score
Get the complete analysis for XTAE:ARAN
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:ARAN has been successfully added to your 
